Synthesis and biological evaluation of novel pyrazole compounds.

A novel dipyrazole ethandiamide compound and acid chloride of pyrazolo[3,4-d]pyrimidine 4(5H)-one were prepared and reacted with a number of nucleophiles. The resultant novel compounds were tested in several in vitro and in vivo assays. Three compounds inhibited the secretion of neurotoxins by human THP-1 monocytic cells at concentrations that were not toxic to these cells. They also partially inhibited both cyclooxygenase-1 and -2 isoforms. In animal studies, two compounds were notable for their anti-inflammatory activity that was comparable to that of the clinically available cyclooxygenase-2 inhibitor celecoxib. Modeling studies by using the molecular operating environment module showed comparable docking scores for the two enantiomers docked in the active site of cyclooxygenase-2.Copyright (C) 2012 American Chemical Society (ACS). All Rights Reserved.; Section Code: 1-3; CA Section Cross-references: 28; CODEN: BMECEP; CAS Registry Numbers: 1245747-32-3P; 1245747-33-4P; 1245747-34-5P; 1245747-35-6P; 1245747-36-7P; 1245747-37-8P Role: PAC (Pharmacological activity), SPN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses) (synthesis and biol. evaluation of novel pyrazole compds.); 64-04-0 (Phenethylamine); 79-37-8 (Oxalyl chloride); 100-63-0; 108-91-8 (Cyclohexanamine); 123-00-2 (4-Morpholinepropanamine); 123-06-8; 618-36-0; 2627-86-3; 3886-69-9 Role: RCT (Reactant), RACT (Reactant or reagent) (synthesis and biol. evaluation of novel pyrazole compds.); 5334-43-0P; 1245747-30-1P; 1245747-31-2P Role: RCT (Reactant), SPN (Synthetic preparation), PREP (Preparation), RACT (Reactant or reagent) (synthesis and biol. evaluation of novel pyrazole compds.)Source type: Electronic(1